Torrent Pharmaceuticals Ltd - 500420 - Board Meeting Outcome for Outcome Of Board Meeting Dated 30-Jul-26
Torrent Pharma's Q1 FY27 cons. revenue grew 55% YoY to ₹4,921 cr, with net profit at ₹566 cr (up 3% YoY). Independent Director Ameera Shah's term concludes on August 1, 2026.
Jul 30 2026 16:59:20
Torrent Pharmaceuticals Ltd - 500420 - Receipt Of Final Listing And Trading Approval For Equity Shares Of The Company Issued And Allotted In Terms Of Scheme Of Amalgamation
Torrent Pharmaceuticals has secured final listing and trading approval for 4.19 crore new equity shares. These shares were issued as part of the amalgamation scheme with J.B. Chemicals & Pharmaceuticals and will commence trading on July 28, 2026, on both NSE and BSE.
Jul 27 2026 19:00:18
Torrent Pharmaceuticals Ltd - 500420 - Allotment Of 4,19,22,416 Fully Paid-Up Equity Shares Of The Company To The Eligible Shareholders Of J. B. Chemicals & Pharmaceuticals Limited As On The Record Date I.E. 17Th July, 2026, In Terms Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders
Torrent Pharma has allotted 4.19 crore fully paid-up equity shares to eligible shareholders of J. B. Chemicals & Pharmaceuticals, increasing its total equity share capital to 38.03 crore shares. This allotment is a consequence of the NCLT-sanctioned amalgamation scheme between the two companies.
Jul 20 2026 12:43:20
Torrent Pharmaceuticals Ltd - 500420 - Dissolution Of Wholly Owned Subsidiary (WOS)
Torrent Pharma has voluntarily dissolved its wholly-owned subsidiary, Curatio Inc. in the Philippines, effective July 10, 2026. This subsidiary had no turnover and an immaterial net worth of 0.02% for FY2026.
Jul 17 2026 22:42:07
Torrent Pharmaceuticals Ltd - 500420 - ESG Rating
Torrent Pharma announced that Crisil ESG Ratings & Analytics has independently assigned the ratings 'Crisil ESG 66' and 'Crisil Core ESG 74'. Crisil ESG Ratings is a SEBI registered ESG Rating Provider.
Jul 17 2026 22:33:45
Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Torrent Pharmaceuticals has scheduled an analyst and investor conference call for July 30, 2026, at 05:30 P.M. The purpose of the call is to discuss the company's financial performance for the quarter ended June 30, 2026 (Q1 FY27).
Jul 17 2026 19:04:42
Torrent Pharmaceuticals Ltd - 500420 - Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results (With Limited Review) For The Quarter Ended On 30-Jun-26.
Torrent Pharma's Board of Directors will convene on July 30, 2026. The agenda includes the consideration and approval of the Q1 FY27 financial results, covering the quarter ended June 30, 2026.
Jul 16 2026 14:53:49
Read More